In his first big merger of the year, Charles Ruck helped biotechnology giant Amgen Inc. acquire the biotech company Tularik Inc. for $1.3 billion.
Ruck is a mergers and acquisitions partner in the corporate department of Latham & Watkins. In 2002, Ruck served on the team that guided Amgen Inc.’s $17.7 billion merger with the drug company Immunex. Founded in 1980, Amgen creates products with the latest advancements in molecular biology, and now bills itself as the world’s largest biotechnology company. He also advised the pharmaceutical company TheraSense when it was acquired by Abbott Laboratories in a billion-dollar deal.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
